Table 2. Summary of adverse events.
| Symptoms | IVIG | Placebo | IVIG vs. Placebo | IVIG vs. Placebo | ||||
|---|---|---|---|---|---|---|---|---|
| JE (n = 7) | Non-JE (n = 4) | Total(n = 11) | JE (n = 6) | Non-JE (n = 5) | Total(n = 11) | P- value | OR(95% CI) | |
| Fever | 2 (.29) | 2 (0.5) | 4 (.36) | 1 (.17) | 1 (0.2) | 2 (.18) | 0.64 | 2.6 (0.3–29) |
| Dyspnoea | 1(.14) | 2 (0.5) | 3 (.27) | 1 (.17) | 1 (0.2) | 2 (.18) | 1 | 1.7 (0.2–20.1) |
| Vomiting | 0 (0) | 0 (0) | 0 (0) | 1 (.17) | 0 (0) | 1 (0.9) | 1 | 0 (0–18.7) |
| Irritable | 1(.14) | 1 (.25) | 2 (.18) | 2 (.33) | 0 (0) | 2 (.18) | 1 | 1 (0.07–13.5) |
| Non-urticarial skin rash | 0 (0) | 0 (0) | 0 (0) | 1 (.17) | 0 (0) | 1 (0.9) | 1 | 0 (0–18.7) |
| Hypotension* | 1(.14) | 0 (0) | 1 (0.9) | 1 (.17) | 0 (0) | 1 (0.9) | 1 | 1 (0–43.7) |
| Melena* | 1(.14) | 0 (0) | 1 (0.9) | 0 (0) | 1 (0.2) | 1 (0.9) | 1 | 1 (0–43.7) |
| Death* | 0 (0) | 1(.14) | 1 (0.9) | 0 (0) | 0 (0) | 0 (0) | 1 | NA |
Data are number of patients (proportion).
* Serious adverse events. NA: not applicable